Drug Profile
BPI 23
Latest Information Update: 03 Aug 2005
Price :
$50
*
At a glance
- Originator New York University
- Class Antibacterials; Peptide antibiotics
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-negative infections; Septic shock
Most Recent Events
- 15 Jul 2005 XOMA has terminated its licence with Zephyr Sciences for BPI-related products
- 10 Nov 2004 BPI 23 has been licensed to Zephyr Sciences worldwide
- 28 Jun 1999 Discontinued-II for Septic shock in European Union (Parenteral)